CAPR - Total Utang marang Modal Capricor Therapeutics, Inc.

Capricor Therapeutics (CAPR) is a biotech player developing cellular therapies where high initial platform costs are offset by the premium pricing of the treatments. The business relies on an exosomal system to combat Duchenne muscular dystrophy, partnering with clinics in the orphan disease segment. This chart shows that the total debt-to-equity ratio is 0.39, while patents and FDA certifications securely protect the niche from new competitors.

The indicator is calculated as the ratio of total liabilities to net shareholders' equity. This metric determines the company's dependence on external financing and the stability of its financial leverage. For Capricor Therapeutics (CAPR), the low debt load is driven by outsourcing production through contracts with biopharmaceutical plants. This strategy reduces the need for capital loans for equipment. The company's leverage history confirms a conservative approach to liability management.